• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

2000-2005 年前列腺特异性抗原检测的使用趋势。

Trends in prostate-specific antigen test use, 2000-2005.

机构信息

Institute for Health, Social and Community Research, Shaw University, Raleigh, NC 27601, USA.

出版信息

Public Health Rep. 2011 Mar-Apr;126(2):228-39. doi: 10.1177/003335491112600214.

DOI:10.1177/003335491112600214
PMID:21387953
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3056036/
Abstract

OBJECTIVE

This study examined prostate-specific antigen (PSA) test use among men and identified sociodemographic and health-related characteristics associated with its use over time.

METHODS

The National Health Interview Survey collected information on PSA test use among 16,058 men > or = 40 years of age in 2000 and 2005. We examined two outcomes: (1) having had a recent (within two years) screening PSA test and (2) having had three or more PSA tests in the past five years (to indicate frequent use).

RESULTS

Marital status, family history of prostate cancer, and having seen a doctor in the past year differed over time in the unadjusted model. In the adjusted model, recent PSA screening decreased from 2000 to 2005 for single, never-married men, but increased for men with chronic diseases. Frequent PSA test use increased for men with a family history of prostate cancer, men with chronic diseases, and men who had seen a physician in the past year. Significant correlates of higher recent PSA test use included being older, married, and of black race/ethnicity; having higher levels of education and income, health-care coverage, and a usual place of health care; and increased comorbidity.

CONCLUSION

Major organizations are not in agreement about the efficacy of prostate cancer screening; however, men > or = 40 years of age continue to use the PSA test. Both recent screening and frequent testing showed variability during the study period and may have implications for the ongoing randomized clinical trials that are expected to clarify whether early detection of prostate cancer with PSA testing increases survival.

摘要

目的

本研究调查了男性进行前列腺特异性抗原(PSA)检测的情况,并确定了与 PSA 检测随时间推移而使用相关的社会人口学和健康相关特征。

方法

国家健康访谈调查收集了 2000 年和 2005 年 16058 名年龄≥40 岁男性进行 PSA 检测的信息。我们研究了两个结果:(1)最近(两年内)进行了筛查性 PSA 检测,(2)过去五年内进行了三次或更多次 PSA 检测(表示频繁使用)。

结果

在未调整模型中,未婚男性和已婚男性的婚姻状况、前列腺癌家族史以及过去一年中看过医生的情况随时间发生了变化。在调整模型中,过去一年中患有慢性病的单身、从未结婚的男性最近进行 PSA 筛查的比例有所增加,但对于患有慢性病的男性则有所减少。有前列腺癌家族史、患有慢性病和过去一年看过医生的男性频繁进行 PSA 检测的比例增加。最近 PSA 检测使用率较高的显著相关因素包括年龄较大、已婚、为黑种人/西班牙裔;受教育程度和收入较高、有医疗保险、有常规医疗服务点;以及共病率较高。

结论

主要组织对前列腺癌筛查的疗效存在分歧;然而,年龄≥40 岁的男性仍在继续使用 PSA 检测。最近的筛查和频繁的检测在研究期间均表现出变异性,这可能对正在进行的随机临床试验产生影响,这些临床试验有望阐明使用 PSA 检测早期发现前列腺癌是否能提高生存率。

相似文献

1
Trends in prostate-specific antigen test use, 2000-2005.2000-2005 年前列腺特异性抗原检测的使用趋势。
Public Health Rep. 2011 Mar-Apr;126(2):228-39. doi: 10.1177/003335491112600214.
2
Patterns in prostate-specific antigen test use and digital rectal examinations in the Behavioral Risk Factor Surveillance System, 2002-2006.2002 - 2006年行为危险因素监测系统中前列腺特异性抗原检测的使用模式及直肠指检情况
J Natl Med Assoc. 2009 Apr;101(4):316-24. doi: 10.1016/s0027-9684(15)30878-6.
3
Use of the prostate-specific antigen test among U.S. men: findings from the 2005 National Health Interview Survey.美国男性中前列腺特异性抗原检测的使用情况:2005年全国健康访谈调查结果
Cancer Epidemiol Biomarkers Prev. 2008 Mar;17(3):636-44. doi: 10.1158/1055-9965.EPI-07-2709.
4
A population-based survey of prostate-specific antigen testing among California men at higher risk for prostate carcinoma.一项针对加利福尼亚州患前列腺癌风险较高男性的前列腺特异性抗原检测的基于人群的调查。
Cancer. 2006 Feb 15;106(4):765-74. doi: 10.1002/cncr.21673.
5
Prostate cancer screening trends in a large, integrated health care system.大型综合医疗保健系统中的前列腺癌筛查趋势
Perm J. 2012 Summer;16(3):4-9. doi: 10.7812/TPP/12.969.
6
Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement.前列腺癌筛查:美国预防服务工作组推荐声明。
JAMA. 2018 May 8;319(18):1901-1913. doi: 10.1001/jama.2018.3710.
7
Decrease in Prostate Cancer Testing Following the US Preventive Services Task Force (USPSTF) Recommendations.美国预防服务工作组(USPSTF)发布建议后前列腺癌检测率下降。
J Am Board Fam Med. 2015 Jul-Aug;28(4):491-3. doi: 10.3122/jabfm.2015.04.150062.
8
Low-Value Prostate-Specific Antigen Screening in Older Males.老年男性低价值前列腺特异性抗原筛查。
JAMA Netw Open. 2023 Apr 3;6(4):e237504. doi: 10.1001/jamanetworkopen.2023.7504.
9
Prostate cancer screening practices in a large, integrated health system: 2007-2014.大型综合医疗系统中的前列腺癌筛查实践:2007 - 2014年
BJU Int. 2017 Aug;120(2):257-264. doi: 10.1111/bju.13793. Epub 2017 Feb 26.
10
Contemporary National Trends of Prostate Cancer Screening Among Privately Insured Men in the United States.美国私人保险男性前列腺癌筛查的当代全国趋势。
Urology. 2016 Nov;97:111-117. doi: 10.1016/j.urology.2016.06.067. Epub 2016 Aug 12.

引用本文的文献

1
Prostate-specific antigen (PSA) screening rates and factors associated with screening in Eastern Canadian men: Findings from cross-sectional survey data.加拿大东部男性的前列腺特异性抗原(PSA)筛查率及与筛查相关的因素:横断面调查数据的研究结果
Can Urol Assoc J. 2020 Jul;14(7):E319-E327. doi: 10.5489/cuaj.6072.
2
Emerging cancer incidence, mortality, hospitalisation and associated burden among Australian cancer patients, 1982 - 2014: an incidence-based approach in terms of trends, determinants and inequality.1982-2014 年澳大利亚癌症患者的癌症发病率、死亡率、住院率及相关负担变化趋势:基于发病率的趋势、决定因素和不平等研究。
BMJ Open. 2019 Dec 15;9(12):e031874. doi: 10.1136/bmjopen-2019-031874.
3
Association Between Antidiabetic Medications and Prostate-Specific Antigen Levels and Biopsy Results.抗糖尿病药物与前列腺特异性抗原水平及活检结果的相关性。
JAMA Netw Open. 2019 Nov 1;2(11):e1914689. doi: 10.1001/jamanetworkopen.2019.14689.
4
Prostate Cancer Mortality-To-Incidence Ratios Are Associated with Cancer Care Disparities in 35 Countries.前列腺癌死亡率与发病率之比与 35 个国家的癌症护理差距有关。
Sci Rep. 2017 Jan 4;7:40003. doi: 10.1038/srep40003.
5
Determinants of Prostate Cancer Screening Intentions of Young Black Men Aged 18 to 40 Years.18至40岁年轻黑人男性前列腺癌筛查意愿的决定因素
J Racial Ethn Health Disparities. 2016 Nov 18. doi: 10.1007/s40615-016-0305-1.
6
Prostate-Specific Antigen Screening: Time to Change the Dominant Forces on the Pendulum.前列腺特异性抗原筛查:是时候改变钟摆上的主导力量了。
J Clin Oncol. 2016 Oct 10;34(29):3499-3501. doi: 10.1200/JCO.2016.67.8938.
7
Opportunities and challenges for the use of large-scale surveys in public health research: a comparison of the assessment of cancer screening behaviors.在公共卫生研究中使用大规模调查的机遇与挑战:癌症筛查行为评估的比较
Cancer Epidemiol Biomarkers Prev. 2015 Jan;24(1):3-14. doi: 10.1158/1055-9965.EPI-14-0568. Epub 2014 Oct 9.
8
Prostate-specific antigen (PSA) screening and follow-up investigations in Māori and non-Māori men in New Zealand.新西兰毛利族和非毛利族男性的前列腺特异性抗原(PSA)筛查及后续调查。
BMC Fam Pract. 2014 Aug 26;15:145. doi: 10.1186/1471-2296-15-145.
9
Prostate specific antigen testing is associated with men's psychological and physical health and their healthcare utilisation in a nationally representative sample: a cross-sectional study.一项横断面研究:在全国代表性样本中,前列腺特异性抗原检测与男性的心理和身体健康及其医疗保健利用情况相关。
BMC Fam Pract. 2014 Jun 17;15:121. doi: 10.1186/1471-2296-15-121.
10
Low uptake of colorectal cancer screening among African Americans in an integrated Veterans Affairs health care network.在一个综合的退伍军人事务医疗保健网络中,非裔美国人对结直肠癌筛查的接受率较低。
Gastrointest Endosc. 2014 Aug;80(2):291-8. doi: 10.1016/j.gie.2014.01.045. Epub 2014 Mar 25.

本文引用的文献

1
Correlates of prostate-specific antigen testing in a large multiethnic cohort.多民族大队列中前列腺特异性抗原检测的相关因素。
Am J Manag Care. 2009 Nov;15(11):793-9.
2
Effect of population trends in body mass index on prostate cancer incidence and mortality in the United States.美国体重指数的人口趋势对前列腺癌发病率和死亡率的影响。
Cancer Epidemiol Biomarkers Prev. 2009 Mar;18(3):808-15. doi: 10.1158/1055-9965.EPI-08-0784. Epub 2009 Mar 3.
3
Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis.前列腺癌男性患者的诊断前体重指数、血浆C肽浓度与前列腺癌特异性死亡率:一项长期生存分析
Lancet Oncol. 2008 Nov;9(11):1039-47. doi: 10.1016/S1470-2045(08)70235-3. Epub 2008 Oct 3.
4
Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement.前列腺癌筛查:美国预防服务工作组建议声明
Ann Intern Med. 2008 Aug 5;149(3):185-91. doi: 10.7326/0003-4819-149-3-200808050-00008.
5
PSA-based screening for prostate cancer: how does it compare with other cancer screening tests?基于前列腺特异性抗原(PSA)的前列腺癌筛查:与其他癌症筛查测试相比如何?
Eur Urol. 2008 Aug;54(2):262-73. doi: 10.1016/j.eururo.2008.05.032. Epub 2008 May 27.
6
Racial differences in prostate cancer screening by family history.基于家族史的前列腺癌筛查中的种族差异。
Ann Epidemiol. 2008 Jul;18(7):579-83. doi: 10.1016/j.annepidem.2008.02.004. Epub 2008 May 16.
7
Use of the prostate-specific antigen test among U.S. men: findings from the 2005 National Health Interview Survey.美国男性中前列腺特异性抗原检测的使用情况:2005年全国健康访谈调查结果
Cancer Epidemiol Biomarkers Prev. 2008 Mar;17(3):636-44. doi: 10.1158/1055-9965.EPI-07-2709.
8
Fear of recurrence, symptom burden, and health-related quality of life in men with prostate cancer.前列腺癌男性患者对复发的恐惧、症状负担及健康相关生活质量
Urology. 2008 Dec;72(6):1269-73. doi: 10.1016/j.urology.2007.12.084. Epub 2008 Mar 17.
9
Prostate-specific antigen and prostate cancer: prediction, detection and monitoring.前列腺特异性抗原与前列腺癌:预测、检测及监测
Nat Rev Cancer. 2008 Apr;8(4):268-78. doi: 10.1038/nrc2351.
10
How should PSA screening efforts be focused to prevent underdiagnosis and overdiagnosis of prostate cancer?前列腺特异性抗原(PSA)筛查工作应如何聚焦,以防止前列腺癌的漏诊和过度诊断?
Nat Clin Pract Urol. 2008 Apr;5(4):172-3. doi: 10.1038/ncpuro1051. Epub 2008 Mar 4.